Latest Cisplatin Stories
Breast cancer patients face many horrors, including those that arise when fighting the cancer itself. Medications given during chemotherapy can have wicked side effects, including vomiting, dizziness, anemia and hair loss.
For years, research has hinted that the time of day that cancer patients receive chemotherapy can impact their chances of survival. But the lack of a clear scientific explanation for this finding has kept clinicians from considering timing as a factor in treatment.
A precious metal never used in a clinical setting is being developed as a next-generation cancer treatment, British researchers report. University of Warwick researchers are working with the metal, osmium, which is related to platinum and is used to treat cancers as part of the drug cisplatin, the university said in a news release. The Department of Chemistry researchers are seeking partners to help develop osmium through more extensive biological tests. While cisplatin is successful...
Phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than other drugs, U.S. researchers said.
A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal Proceedings of the National Academy of Sciences.
CALGARY, Nov. 14 /PRNewswire-FirstCall/ -- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that a poster presentation authored by Dr.
Alimta has received US approval for use as a first-line therapy in locally advanced and metastatic non-small cell lung cancer in combination with cisplatin.
Eli Lilly and Company has received approval from the FDA for the use of Alimta in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer, for patients with nonsquamous histology. This marks the third US indication for Alimta.
INDIANAPOLIS, Sept. 29 /PRNewswire-FirstCall/ -- Eli Lilly and Company announced today it received approval from the U.S.
U.S. researchers say they have linked a genetic variant of a protein to resistance to the chemotherapy drug cisplatin.